Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lisa A. Porter is active.

Publication


Featured researches published by Lisa A. Porter.


Journal of Cell Biology | 2002

Human speedy: A novel cell cycle regulator that enhances proliferation through activation of Cdk2

Lisa A. Porter; Ryan W. Dellinger; John A. Tynan; Elizabeth A. Barnes; Monica Kong; Jean-Luc Lenormand; Daniel J. Donoghue

The decision for a cell to self-replicate requires passage from G1 to S phase of the cell cycle and initiation of another round of DNA replication. This commitment is a critical one that is tightly regulated by many parallel pathways. Significantly, these pathways converge to result in activation of the cyclin-dependent kinase, cdk2. It is, therefore, important to understand all the mechanisms regulating cdk2 to determine the molecular basis of cell progression. Here we report the identification and characterization of a novel cell cycle gene, designated Speedy (Spy1). Spy1 is 40% homologous to the Xenopus cell cycle gene, X-Spy1. Similar to its Xenopus counterpart, human Speedy is able to induce oocyte maturation, suggesting similar biological characteristics. Spy1 mRNA is expressed in several human tissues and immortalized cell lines and is only expressed during the G1/S phase of the cell cycle. Overexpression of Spy1 protein demonstrates that Spy1 is nuclear and results in enhanced cell proliferation. In addition, flow cytometry profiles of these cells demonstrate a reduction in G1 population. Changes in cell cycle regulation can be attributed to the ability of Spy1 to bind to and prematurely activate cdk2 independent of cyclin binding. We demonstrate that Spy1-enhanced cell proliferation is dependent on cdk2 activation. Furthermore, abrogation of Spy1 expression, through the use of siRNA, demonstrates that Spy1 is an essential component of cell proliferation pathways. Hence, human Speedy is a novel cell cycle protein capable of promoting cell proliferation through the premature activation of cdk2 at the G1/S phase transition.


Cancer Research | 2008

The Spy1/RINGO Family Represents a Novel Mechanism Regulating Mammary Growth and Tumorigenesis

Azadeh Golipour; Dorothy Myers; Tiffany N. Seagroves; Daniel J. Murphy; Gerard I. Evan; Daniel J. Donoghue; Roger A. Moorehead; Lisa A. Porter

Spy1A is a unique cell cycle activator known to mediate cell cycle progression and override the DNA damage response. This study focused on determining the role of this protein on postnatal mammary gland morphogenesis and neoplasia. Herein, we show that Spy1A levels are tightly regulated during mammary gland development and that ectopic expression stimulates precocious development and results in disrupted morphology of the gland. This follows the same trend as the oncogene c-Myc, and we show that Spy1A expression is regulated downstream of c-Myc signaling. Importantly, we show that overexpression of Spy1A accelerates tumorigenesis in vivo. Collectively, this work is the first report that the Spy1/RINGO family of proteins may play an essential role in regulating both normal and abnormal growth processes in the breast.


Cell Cycle | 2007

Spy1 enhances phosphorylation and degradation of the cell cycle inhibitor p27.

Christopher W. McAndrew; Randy F. Gastwirt; April N. Meyer; Lisa A. Porter; Daniel J. Donoghue

The cyclin dependent kinase inhibitor (CKI) p27Kip1 binds to cyclin E/CDK2 complexes and prevents premature S-phase entry. During late G1 and throughout S phase, p27 phosphorylation at T187 leads to its subsequent degradation, which relieves CDK2 inhibition to promote cell cycle progression. However, critical events that trigger CDK2 complexes to phosphorylate p27 remain unclear. Utilizing recombinant proteins, we demonstrate that human Speedy (Spy1) activates CDK2 to phosphorylate p27 at T187 in vitro. Addition of Spy1 or Spy1/CDK2 to a preformed, inhibited cyclin E/CDK2/p27 complex also promoted this phosphorylation. Furthermore, Spy1 protected cyclin E/CDK2 from p27 inhibition toward histone H1, in vitro. Inducible Spy1 expression in U2OS cells reduced levels of endogenous p27 and exogenous p27WT, but not a p27T187A mutant. Additionally, Spy1 expression in synchronized HeLa cells enhanced T187 phosphorylation and degradation of endogenous p27 in late G1 and throughout S phase. Our studies provide evidence that Spy1 expression enhances CDK2-dependent p27 degradation during late G1 and throughout S phase.


Cancer Cell | 2014

The cyclin-like protein Spy1 regulates growth and division characteristics of the CD133+ population in human glioma.

Dorota Lubanska; Brenna A. Market-Velker; Ana C. deCarvalho; Tom Mikkelsen; Elizabeth Fidalgo da Silva; Lisa A. Porter

The heterogeneity of brain cancers, as most solid tumors, complicates diagnosis and treatment. Identifying and targeting populations of cells driving tumorigenesis is a top priority for the cancer biology field. This is not a trivial task; considerable variance exists in the driving mutations, identifying markers, and evolutionary pressures influencing initiating cells in different individual tumors. Despite this, the ability to self-renew and differentiate must be conserved to reseed a heterogeneous tumor mass. Focusing on one example of a tumor-initiating cell population, we demonstrate that the atypical cyclin-like protein Spy1 plays a role in balancing the division properties of glioma cells with stemness properties. This mechanistic insight may provide new opportunities for therapeutic intervention of brain cancer.


Neuroscience | 2011

The level and distribution of the GABABR2 receptor subunit in the rat's central auditory system

Lena Jamal; Huiming Zhang; P. G. Finlayson; Lisa A. Porter

The GABA(B) receptor is important for the function of auditory neurons. We used Western blotting and immunohistochemical methods to examine the level and localization of GABA(B)R2, a required subunit of a functional GABA(B) receptor, in the rats central auditory system. Results revealed that this subunit was expressed throughout the auditory system with the level being high in the layers I-V of the auditory cortex, medial geniculate nucleus, dorsomedial and lateral parts of the inferior colliculus, and the molecular and fusiform cell layers of the dorsal cochlear nucleus. Labeled cell bodies were found in all the areas showing immunoreactivity. Neuropil labeling was strong in areas with high overall levels of immunoreactivity. Regional distributions of the receptor subunit revealed clear boundaries of some auditory subnuclei including the dorsal and ventral cochlear nuclei and the lateral superior olivary nucleus. Differences in immunoreactivity were found between the central nucleus and the dorsal cortex of the inferior colliculus and between the dorsal and ventral parts of the ventral nucleus of the lateral lemniscus, although no clear boundaries were observed. No differences in immunoreactivity were found between the core and the belt areas of the auditory cortex and among the subdivisions of the medial geniculate nucleus. The regional distribution of the receptor subunit in auditory structures is consistent with inputs to these structures and the cellular localization of the receptor in auditory neurons supports the contribution of the GABA(B) receptor to synaptic responses in these neurons.


Journal of Biological Chemistry | 2009

The Cyclin-dependent Kinase Activator, Spy1A, Is Targeted for Degradation by the Ubiquitin Ligase NEDD4

Mohammad Al Sorkhy; Ryan Craig; Brenna Market; Ryan Ard; Lisa A. Porter

Spy1A is a cyclin-like protein required for progression through the G1/S phase of the cell cycle. Elevated Spy1A protein levels have been implicated in tumorigenesis and are attributed to overriding the DNA damage response and enhancing cell proliferation. Understanding how Spy1A is produced and degraded is essential in resolving how it contributes to normal and abnormal growth processes. Herein, we demonstrate that Spy1A is degraded in a cell cycle-dependent manner during mitosis via the ubiquitin-proteasome system. We have resolved the E3 ligase and essential phosphorylation sites mediating Spy1A degradation. Furthermore, we have determined that non-degradable forms of Spy1A do not trigger cell cycle arrest but, rather, contribute to uncontrolled cell growth. Further investigation into the regulation of Spy1A may reveal novel strategies for understanding the etiology and progression of specific growth disorders.


Ozone-science & Engineering | 2015

Effect of Media on Biofilter Performance Following Ozonation of Secondary Treated Municipal Wastewater Effluent: Sand vs. GAC

Michael James Reaume; Rajesh Seth; Kerry N. McPhedran; Elizabeth Fidalgo da Silva; Lisa A. Porter

Ozone has been shown to be effective in the transformation of several chemicals of emerging concern that escape the wastewater treatment process, but there is concern whether toxic transformation products are formed. Two parallel biofilter columns with granular activated carbon (GAC) and filter sand following a pilot-scale ozone unit to treat secondary treated municipal wastewater were studied. Results show reduced wastewater genotoxicity following ozonation and further reduction following biofiltration. The BAC biofilter outperformed the sand biofilter in terms of reduction in both organics and genotoxicity. Biofilter performance correlated with biological indicators (dissolved oxygen reduction and effluent E. coli counts) but not with ATP bioactivity measurements. Limited bacterial (E. coli) regrowth was observed in treated effluent from both biofilters.


Cell Cycle | 2011

The tumor suppressor tuberin regulates mitotic onset through the cellular localization of cyclin B1

Elizabeth Fidalgo da Silva; Shora B. Ansari; Jiamila Maimaiti; Elizabeth A. Barnes; Monica Kong-Beltran; Daniel J. Donoghue; Lisa A. Porter

Tuberous sclerosis is a multi-organ disorder characterized by the formation of benign tumors, called hamartomas, which affects more than 1 million people worldwide. The syndrome is initiated by a mutation in one of two tumor suppressor genes, TSC1 or TSC2, that encode for the proteins hamartin and tuberin, respectively. Herein, we demonstrate that tuberin binds and regulates the G2/M cyclin, cyclin B1. We have determined that this binding region encompasses a mutational hotspot within tuberin that is implicated in some of the most severe cases of TS. Mimicking a mutation found in a subset of patients with tuberous sclerosis, we found a significant reduction in the binding between tuberin and cyclin B1. Functionally, our data supports that tuberin plays a role in regulating the cellular localization of cyclin B1. These results demonstrate a novel and clinically relevant mechanism, where tuberin functions in mitotic onset.


BMC Cancer | 2016

Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis

Zainab A. Bazzi; Danielle Lanoue; Mouhanned El-Youssef; Rocco Romagnuolo; Janice Tubman; Dora Cavallo-Medved; Lisa A. Porter; Michael B. Boffa

BackgroundThrombin activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen, which can be converted to activated TAFI (TAFIa) through proteolytic cleavage by thrombin, plasmin, and most effectively thrombin in complex with the endothelial cofactor thrombomodulin (TM). TAFIa is a carboxypeptidase that cleaves carboxyl terminal lysine and arginine residues from protein and peptide substrates, including plasminogen-binding sites on cell surface receptors. Carboxyl terminal lysine residues play a pivotal role in enhancing cell surface plasminogen activation to plasmin. Plasmin has many critical functions including cleaving components of the extracellular matrix (ECM), which enhances invasion and migration of cancer cells. We therefore hypothesized that TAFIa could act to attenuate metastasis.MethodsTo assess the role of TAFIa in breast cancer metastasis, in vitro migration and invasion assays, live cell proteolysis and cell proliferation using MDA-MB-231 and SUM149 cells were carried out in the presence of a TAFIa inhibitor, recombinant TAFI variants, or soluble TM.ResultsInhibition of TAFIa with potato tuber carboxypeptidase inhibitor increased cell invasion, migration and proteolysis of both cell lines, whereas addition of TM resulted in a decrease in all these parameters. A stable variant of TAFIa, TAFIa-CIIYQ, showed enhanced inhibitory effects on cell invasion, migration and proteolysis. Furthermore, pericellular plasminogen activation was significantly decreased on the surface of MDA-MB-231 and SUM149 cells following treatment with various concentrations of TAFIa.ConclusionsTaken together, these results indicate a vital role for TAFIa in regulating pericellular plasminogen activation and ultimately ECM proteolysis in the breast cancer microenvironment. Enhancement of TAFI activation in this microenvironment may be a therapeutic strategy to inhibit invasion and prevent metastasis of breast cancer cells.


computational intelligence in bioinformatics and computational biology | 2015

Identifying differentially expressed transcripts associated with prostate cancer progression using RNA-Seq and machine learning techniques

Siva Singireddy; Abed Alkhateeb; Iman Rezaeian; Luis Rueda; Dora Cavallo-Medved; Lisa A. Porter

Background: Prostate cancer is complicated by a high level of unexplained variability in the aggressiveness of newly diagnosed disease. Given that this is one of the most prevalent cancers worldwide, finding biomarkers to effectively stratify high risk patient populations is a vital next step in improving survival rates and quality of life after treatment. Materials and Methods: In this study, we selected a dataset consisting of 106 prostate cancer samples, which represent various stages of prostate cancer and developed by RNA-Seq technology. Our objective is to identify differentially expressed transcripts associated with prostate cancer progression using pair-wise stage comparisons. Results: Using machine learning techniques, we identified 44 transcripts that are correlated to different stages of progression. Expression of an identified transcript, USP13, is reduced in stage T3 in comparison with stage T2c, a pattern also observed in breast cancer tumourigenesis. We also identified another differentially expressed transcript, PTGFR, which has also been reported to be involved in prostate cancer progression and has also been linked to breast, ovarian and renal cancers. Conclusions: The results support the use of RNA-Seq along with machine learning techniques as an essential tool in identifying potential biomarkers for prostate cancer progression. Further studies elucidating the biochemical role of identified transcripts in vitro are crucial in validating the use of these biomarkers in the prediction of disease progression and development of effective therapeutic strategies.

Collaboration


Dive into the Lisa A. Porter's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge